Prestige BioPharma Limited

KOSE:A950210 Stock Report

Market Cap: ₩177.3b

Prestige BioPharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

So-Yeon Park

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure9.3yrs
CEO ownership15.4%
Management average tenureno data
Board average tenure4.7yrs

Recent management updates

Recent updates

Here's Why Prestige BioPharma (KRX:950210) Can Manage Its Debt Despite Losing Money

Oct 23
Here's Why Prestige BioPharma (KRX:950210) Can Manage Its Debt Despite Losing Money

CEO

So-Yeon Park (61 yo)

9.3yrs

Tenure

Ms. So-yeon Park is Chairman and CEO at Prestige BioPharma Limited and has been its director since July 13, 2015.

Board Members

NamePositionTenureCompensationOwnership
So-Yeon Park
Chairman & CEO9.3yrsno data15.4%
₩ 27.3b
Jinwoo Kim
CFO & Director7.9yrsno datano data
Kang Lin Ong
Independent Director1.2yrsno datano data
Kue-Ho Bang
Independent Director4.8yrsno datano data
Seung-Joo Oh
Independent Director4.8yrsno datano data
Eui Kyung Lee
Independent Director4.6yrsno datano data
Kyunghee Jeon
Independent Director4.6yrsno datano data
Kok Fatt Lee
Independent Director4.6yrsno datano data

4.7yrs

Average Tenure

58yo

Average Age

Experienced Board: A950210's board of directors are considered experienced (4.7 years average tenure).